Metabolic Disorders due to Lysosomal Dysfunction in Dogs (Lysosomal Storage Disease, Mucopolysaccharidoses)
- Synonyms: MPS
- Occurrence: very rare
- Location of disease: General/Whole body
When to visit the vet?
Non-urgent see a veterinarian within 2–3 days
If the condition worsens / symptoms persist, consult a veterinarian.
Definition
Mucopolysaccharidoses (MPS) are a group of rare, genetically determined lysosomal storage diseases caused by a deficiency in specific enzymes. These enzymes are responsible for breaking down glycosaminoglycans (GAGs) in the cells. In dogs, this deficiency leads to an accumulation of GAGs, resulting in a variety of clinical symptoms that can predominantly affect the skeleton, eyes, heart function, and the central nervous system (CNS).
The most important facts at a glance
Mucopolysaccharidoses (MPS) are rare, genetically determined Diseases in Dogs caused by defects in enzymes necessary for the breakdown of glycosaminoglycans (GAGs). These disorders lead to an accumulation of GAGs in the lysosomes of cells, resulting in damage to various tissues and a variety of clinical symptoms. Common symptoms include Dwarfism, altered bone growth, joint degeneration, liver enlargement, Balance disorders, and eye diseases. The disease is inherited autosomal-recessively, meaning both parents must carry the defective gene to pass on the disease.
Diagnosis is made through clinical examinations, laboratory tests, and genetic analyses to identify the specific mutation. A definitive cure is currently not possible, but symptomatic treatments such as physiotherapy, Pain relievers, and enzyme replacement therapies can improve the quality of life. The prognosis varies depending on the severity of the disease, and early diagnosis can slow the progression of symptoms. For prevention, genetic tests and targeted breeding decisions are crucial to prevent the transmission of the disease.
Research focuses on the genetic basis of MPS and on the development of new treatment approaches such as enzyme replacement and gene therapies. These efforts could not only improve treatment in dogs but also provide valuable insights for human medicine. Collaboration between various disciplines is crucial to deepen the understanding of the disease and develop effective therapies.
Causes
The scientific basis of mucopolysaccharidoses lies in the biochemical function of glycosaminoglycans, also known as mucopolysaccharides. These long carbohydrate chains are essential components of connective tissues, cartilage, skin, and other body structures. Normally, GAGs are continuously broken down and recycled, a process that takes place in the lysosomes, the “waste disposal facilities” of the cells.
In dogs with MPS, one of the enzymes needed to break down GAGs is either defective or completely missing. This leads to an accumulation of GAGs within the lysosomes, which disrupts normal cell function and contributes to the clinical symptoms of the disease. The accumulation of these substances causes cell and tissue damage, leading to the characteristic symptoms of the disease.
MPS is caused by genetic mutations, which are usually inherited in an autosomal recessive manner. This means that both parents must be carriers of the defective gene in order to pass the disease on to their offspring. Different types of MPS are caused by mutations in different genes, each coding for a specific enzyme.
Symptoms
The Symptoms: of mucopolysaccharidoses in dogs can vary greatly, depending on the specific form of the disease and the affected enzyme. General symptoms include anomalies of the skeleton, such as abnormal growth, limb deformities, and spinal malformations. These can lead to limited mobility and Pain.
Other common symptoms include eye diseases, such as corneal opacities and retinal degeneration, which can lead to vision loss. Heart problems are also possible, as GAGs can accumulate in the heart muscle and heart valves, leading to heart failure.
In some forms of MPS, neurological symptoms may also occur, indicating involvement of the central nervous system (CNS). These can range from mild Behavioral changes to severe neurological deficits that significantly impair the dog’s quality of life.
Therapy
The therapy of mucopolysaccharidoses in dogs is currently limited and focuses primarily on alleviating symptoms and improving the quality of life of the affected animal. A curative therapy that completely cures the disease is not currently available.
Symptomatic treatment may include physiotherapy, Pain relievers, and anti-inflammatory medications to improve mobility and relieve Pain. Surgical intervention may be necessary for eye diseases to preserve or restore vision.
In some cases, enzyme replacement therapy may be considered, where the missing enzyme is administered as a medication. However, this therapy is complex and expensive and is not available for all forms of MPS.
Prognosis and follow-up care
The prognosis for dogs with mucopolysaccharidoses varies depending on the severity of the disease and the specific MPS form. Some dogs can achieve a relatively good quality of life with appropriate symptomatic treatment, while others may have a shorter life expectancy due to more severe symptoms.
Early diagnosis and intervention can help improve the quality of life and slow the progression of the disease, even if it is ultimately not curable. The dog’s quality of life and the owners’ ability to provide the necessary care also play an important role in the prognosis.
Prevention
The prevention of mucopolysaccharidoses focuses primarily on genetic counseling and avoiding the breeding of carrier animals. Genetic tests can identify carriers, making it possible to make targeted breeding decisions to prevent the transmission of the disease.
For breeders, it is important to integrate genetic tests into their breeding programs to minimize the risk of spreading this severe genetic disease. Dogs that are carriers of the genetic mutation should not be used for breeding, unless they are paired with a partner who is free of the mutation.
Furthermore, educational programs for pet owners and breeders can help raise awareness of MPS and improve the recognition and management of the disease. Such programs can provide information on symptoms, diagnostic options, and treatment methods to improve the lives of affected dogs and their owners.
Outlook on current research
Mucopolysaccharidoses (MPS) are a group of lysosomal storage diseases caused by genetic defects that prevent the breakdown of glycosaminoglycans (GAGs). These disorders are rare in dogs, but when they occur, they lead to an accumulation of GAGs in various tissues and a variety of clinical symptoms. Research into MPS in dogs focuses on better understanding the genetic basis of these diseases and developing potential treatments.
Current studies are identifying specific genes affected in dogs with various forms of MPS. Advances in genetics have made it possible to develop targeted genetic tests that can help identify carrier dogs and thus prevent the breeding of affected animals. These tests are particularly important for breeds where MPS is more common.
Another important research area is the development of therapy approaches, including enzyme replacement therapy and gene therapy. Enzyme replacement therapy attempts to replace the missing or defective enzyme, while gene therapy aims to correct or replace defective genes. Both approaches have shown promising results in preclinical studies in other animal species, and efforts are underway to adapt these therapies for dogs as well.
Additionally, research is being conducted to improve symptomatic treatment strategies to enhance the quality of life for affected dogs. This includes the development of medications for Pain relief and improved mobility, as well as physiotherapy programs specifically tailored to the needs of dogs with MPS.
Another research area investigates the role of nutrition and dietary supplements in supporting the metabolism of affected dogs. By slowing the progression of the disease or alleviating symptoms, an adapted diet could make a valuable contribution to the quality of life of these animals.
In the future, research into MPS in dogs could not only benefit affected animals but also provide valuable insights for the treatment of MPS in humans. Since dogs are genetically and physiologically quite similar to humans, they often serve as model organisms in medical research. Advances in the treatment of MPS in dogs could thus have a dual benefit.
Collaboration between veterinarians, geneticists, and pharmacists is crucial to deepen the understanding of MPS in dogs and to develop new therapy options. Interdisciplinary approaches are being pursued in research centers worldwide to decipher the genetic causes of MPS and to find effective treatments.
In summary, research into MPS in dogs represents a dynamic and promising field. While many challenges still need to be overcome, ongoing studies offer hope for better diagnostic tools and therapeutic options that could significantly improve the lives of dogs with MPS.
Frequently Asked Questions (FAQs)
1. What are Mucopolysaccharidoses (MPS) in Dogs?
2. What Symptoms: do dogs with MPS show?
3. How is MPS diagnosed in dogs?
4. Which breeds are most commonly affected by MPS?
5. Is there a cure for MPS in dogs?
6. Can dogs with MPS lead a normal life?
7. How should owners manage a dog suffering from MPS?
8. Can MPS be prevented in dogs?
9. What progress is there in research on MPS in dogs?
10. Is MPS in dogs similar to that in humans?
Literature
- Faller, K. M. E., Ridyard, A. E., Gutierrez-Quintana, R., Rupp, A., Kun-Rodrigues, C., Orme, T., Tylee, K. L., Church, H. J., Guerreiro, R., & Bras, J. (2020). A deletion of IDUA exon 10 in a family of Golden Retriever dogs with an attenuated form of mucopolysaccharidosis type I. Journal of Veterinary Internal Medicine, 34(5), 1813–1824. https://doi.org/10.1111/jvim.15868
- Wang, P., Margolis, C., Lin, G., Buza, E. L., Quick, S., Raj, K., Han, R., & Giger, U. (2018). Mucopolysaccharidosis type VI in a Great Dane caused by a nonsense mutation in the ARSB gene. Veterinary Pathology, 55(2), 286–293. https://doi.org/10.1177/0300985817732115
- Pérez, M. L., Kridel, H. A., Gallagher, A., Sheppard, B. J., Reese, S., Kondo, H., Alleman, R., & Giger, U. (2015). Mucopolysaccharidosis type VI in a juvenile Miniature Schnauzer dog with concurrent hypertriglyceridemia, necrotizing pancreatitis, and diabetic ketoacidosis. Canadian Veterinary Journal, 56(3), 272–277.
- Jolly, R. D., Hopwood, J. J., Marshall, N. R., Jenkins, K. S., Thompson, D. J., Dittmer, K. E., Thompson, J. C., Fedele, A. O., Raj, K., & Giger, U. (2012). Mucopolysaccharidosis type VI in a Miniature Poodle-type dog caused by a deletion in the arylsulphatase B gene. New Zealand Veterinary Journal, 60(3), 183–188. https://doi.org/10.1080/00480169.2011.642791
- Haskins, M. E. (2007). Animal models for mucopolysaccharidosis disorders and their clinical relevance. Acta Paediatrica, 96(455), 56–62. https://doi.org/10.1111/j.1651-2227.2007.00211.x
- Ponder, K. P., Melniczek, J. R., Xu, L., Gao, C., Weil, M. A., O’Malley, T. M., O’Donnell, P. A., Mazrier, H., Ellinwood, N. M., Zweigle, J., Wolfe, J. H., & Haskins, M. E. (2002). Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs. Proceedings of the National Academy of Sciences of the United States of America, 99(20), 13102–13107. https://doi.org/10.1073/pnas.192353499
- Bradbury, A. M., Gurda, B. L., Casal, M. L., Ponder, K. P., Vite, C. H., & Haskins, M. E. (2015). A review of gene therapy in canine and feline models of lysosomal storage disorders. Human Gene Therapy Clinical Development, 26(1), 27–37. https://doi.org/10.1089/humc.2015.002